#United States #New York #Class Action #Levi Korsinsky #Neumora Therapeutics

Class Action Lawsuit Alert for Neumora Therapeutics Investors

On April 4, 2025, Levi & Korsinsky, LLP made a significant announcement regarding a class action lawsuit involving Neumora Therapeutics, Inc. (NASDAQ: NMRA). This formal notification serves to inform investors affected by alleged securities fraud concerning the details of the lawsuit and the critical timeline involved, particularly the lead plaintiff deadline set for April 7, 2025.

What You Need to Know

Class Definition

The class action aims to represent individuals and entities who purchased or acquired common stock in Neumora Therapeutics, Inc. especially during the actions that took place on or about September 15, 2023. Should any investor experience losses during this period, they are encouraged to act before the stated deadline to pursue potential recompense.

Reasons for the Lawsuit

The lawsuit alleges that Neumora's executives made misleading statements and neglected to disclose vital information regarding the company’s clinical trials, specifically concerning their flagship candidate, Navacaprant. Key points of contention include:
1. Neumora purportedly amended the inclusion criteria for its Phase Two trial, which was aimed at justifying the commencement of its Phase Three Program. This modification expanded the patient demographic to include those suffering from moderate to severe Major Depressive Disorder (MDD).
2. Additionally, the company introduced a prespecified analysis in its statistical plan, zeroing in on the same demographic, indicating questionable results in the treatment of MDD.
3. The complaint outlines that the data collected during the Phase Two Trials was insufficient, raising concerns about patient population sizes and gender ratios that failed to provide accurate predictive results for the subsequent KOASTAL-1 study.

Steps for Investors

Affected investors have until April 7, 2025, to request the Court to appoint them as lead plaintiffs. It’s crucial to note that participating in the lawsuit does not necessitate being a lead plaintiff for a potential recovery of losses, as members of the class are entitled to compensation without incurring any out-of-pocket costs or fees.

About Levi & Korsinsky

Having dominated the field of securities litigation for over two decades, Levi & Korsinsky has consistently helped secure hundreds of millions for shareholders facing losses due to fraudulent activities. The firm boasts a specialized team adept at navigating the complexities involved in such cases. Recognized multiple times in the ISS Securities Class Action Services' Top 50 Report, Levi & Korsinsky has solidified its reputation as a frontrunner among U.S. securities litigation firms.

Contact Information

For any investors with concerns or inquiries regarding their eligibility to join the class action or for further guidance, they can reach out to Joseph E. Levi, Esq. or any of the associates at Levi & Korsinsky. Contact details include:

• - Email: [Email Contact]
• - Phone: (212) 363-7500

Investors are encouraged to take action promptly and assess their positions concerning this ongoing legal issue under the vigilant guidance of trusted legal counsel.

Conclusion

As the deadline approaches, it is essential for Neumora Therapeutics investors to stay informed and take necessary action. The impending class action lawsuit not only serves as a precaution against potential financial losses but also represents a collective effort to ensure accountability in corporate governance. Investors should prioritize reviewing their options and making informed decisions as this legal matter unfolds.